US 12,168,045 B2
Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
Gustav Gaudernack, Sandvika (NO); and Audun Tornes, Drammen (NO)
Assigned to Ultimovacs ASA, Oslo (NO)
Filed by Ultimovacs AS, Oslo (NO)
Filed on Aug. 9, 2022, as Appl. No. 17/818,584.
Application 17/818,584 is a continuation of application No. 16/306,352, granted, now 11,419,927, previously published as PCT/EP2017/063589, filed on Jun. 2, 2017.
Claims priority of application No. 16172760 (EP), filed on Jun. 2, 2016.
Prior Publication US 2023/0049012 A1, Feb. 16, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/001157 (2018.08) [A61K 39/0011 (2013.01); A61K 39/00115 (2018.08); A61K 39/001154 (2018.08); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/70 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01)] 32 Claims
 
1. A method of treatment of cancer in a patient, comprising the steps of:
i) inhibiting an immune checkpoint by administering at least one immune checkpoint inhibitor, wherein the at least one immune checkpoint inhibitor is selected from the group consisting of an anti-CTLA-4 antibody or an antigen-binding fragment thereof, an anti-PD-1 antibody or an antigen-binding fragment thereof and an anti-PD-L1 antibody or an antigen-binding fragment thereof, and wherein the at least one immune checkpoint inhibitor down-regulates or blocks the immune checkpoint; and
ii) simultaneously, separately or sequentially administering: a cocktail of polypeptides comprising:
a) a polypeptide consisting of a sequence of SEQ ID NO. 1 or a fragment thereof comprising at least 12 amino acids;
b) a polypeptide consisting of a sequence of SEQ ID NO. 2 or a fragment thereof comprising at least 12 amino acids; and
c) a polypeptide consisting of a sequence of SEQ ID NO. 3 or a fragment thereof comprising at least 12 amino acids,
wherein the method produces a synergistic effect in the treatment of cancer in the patient.